EJ Estlin

719 total citations
25 papers, 454 citations indexed

About

EJ Estlin is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, EJ Estlin has authored 25 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Public Health, Environmental and Occupational Health and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in EJ Estlin's work include Childhood Cancer Survivors' Quality of Life (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Neuroblastoma Research and Treatments (7 papers). EJ Estlin is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Neuroblastoma Research and Treatments (7 papers). EJ Estlin collaborates with scholars based in United Kingdom, United States and Australia. EJ Estlin's co-authors include Gareth J. Veal, A D Pearson, J M Littlewood, I M Bowler, G.A. Amos Burke, S. Murray Yule, Milind Ronghe, Simon Cotterill, Mark L. Bernstein and C B Pratt and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

EJ Estlin

25 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
EJ Estlin United Kingdom 12 137 119 95 82 77 25 454
Maria Grazia Zurlo Italy 13 180 1.3× 140 1.2× 126 1.3× 132 1.6× 80 1.0× 19 579
Hee Young Ju South Korea 13 113 0.8× 63 0.5× 58 0.6× 108 1.3× 108 1.4× 62 508
L. Manil France 15 173 1.3× 49 0.4× 37 0.4× 78 1.0× 41 0.5× 26 617
Bertino United States 11 178 1.3× 130 1.1× 38 0.4× 190 2.3× 90 1.2× 27 520
G. Landbeck Germany 11 107 0.8× 158 1.3× 60 0.6× 90 1.1× 64 0.8× 65 531
Carlos Alemany United States 15 203 1.5× 77 0.6× 29 0.3× 411 5.0× 143 1.9× 40 671
Hideko Tasaka Japan 10 170 1.2× 62 0.5× 33 0.3× 195 2.4× 66 0.9× 20 563
Juliet Hananian United States 9 142 1.0× 245 2.1× 127 1.3× 168 2.0× 122 1.6× 15 645
Wafaa M. Rashed Egypt 9 140 1.0× 56 0.5× 42 0.4× 62 0.8× 25 0.3× 23 400
Patrick Cobb United States 14 96 0.7× 41 0.3× 50 0.5× 301 3.7× 105 1.4× 43 476

Countries citing papers authored by EJ Estlin

Since Specialization
Citations

This map shows the geographic impact of EJ Estlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EJ Estlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EJ Estlin more than expected).

Fields of papers citing papers by EJ Estlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EJ Estlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EJ Estlin. The network helps show where EJ Estlin may publish in the future.

Co-authorship network of co-authors of EJ Estlin

This figure shows the co-authorship network connecting the top 25 collaborators of EJ Estlin. A scholar is included among the top collaborators of EJ Estlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EJ Estlin. EJ Estlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hussein, Dahat A., Sarah V. Holt, Tetyana Klymenko, et al.. (2009). Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. British Journal of Cancer. 101(1). 55–63. 12 indexed citations
2.
McGown, Andrew, et al.. (2009). Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.. PubMed. 29(8). 3103–8. 11 indexed citations
3.
Estlin, EJ, et al.. (2008). The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. Cancer Treatment Reviews. 34(3). 231–246. 9 indexed citations
4.
Leach, Paul, et al.. (2008). Diffuse brainstem gliomas in children: should we or shouldn't we biopsy?. British Journal of Neurosurgery. 22(5). 619–624. 36 indexed citations
5.
Estlin, EJ & Gareth J. Veal. (2003). Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treatment Reviews. 29(4). 253–273. 44 indexed citations
6.
Estlin, EJ. (2002). Novel Targets for Therapy in Paediatric Oncology. 2(2). 141–150. 3 indexed citations
7.
8.
9.
Estlin, EJ, et al.. (2001). Practicalities and ethics of running clinical trials in paediatric oncology — the UK experience. European Journal of Cancer. 37(11). 1394–1398. 4 indexed citations
10.
11.
Estlin, EJ, CR Pinkerton, I J Lewis, et al.. (2001). A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children’s Cancer Study Group Investigation. British Journal of Cancer. 84(1). 11–18. 14 indexed citations
12.
Veal, Gareth J., Melanie Griffin, Elizabeth E. Price, et al.. (2001). A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. British Journal of Cancer. 84(8). 1029–1035. 59 indexed citations
13.
Estlin, EJ, Milind Ronghe, G.A. Amos Burke, & S. Murray Yule. (2000). The Clinical and Cellular Pharmacology Of Vincristine, Corticosteroids, l‐Asparaginase, Anthracyclines and Cyclophosphamide In Relation To Childhood Acute Lymphoblastic Leukaemia. British Journal of Haematology. 110(4). 780–790. 26 indexed citations
14.
Estlin, EJ, et al.. (2000). Optimizing antimetabolite‐based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia. British Journal of Haematology. 110(1). 29–40. 6 indexed citations
15.
Estlin, EJ, Simon Cotterill, C B Pratt, A D Pearson, & Mark L. Bernstein. (2000). Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children’s Cancer Study Group and the Pediatric Oncology Group. Journal of Clinical Oncology. 18(9). 1900–1905. 36 indexed citations
16.
Burke, G.A. Amos, et al.. (1999). The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer. Cancer Treatment Reviews. 25(1). 13–27. 8 indexed citations
17.
Barnes, Michael R., EJ Estlin, G. A. Taylor, et al.. (1999). Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.. PubMed. 5(9). 2548–58. 27 indexed citations
18.
Estlin, EJ, Kathryn Balmanno, A H Calvert, et al.. (1997). The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines. British Journal of Cancer. 76(12). 1579–1585. 3 indexed citations
19.
Estlin, EJ, et al.. (1996). Phase I trials in paediatric oncology — the European perspective. Investigational New Drugs. 14(1). 23–32. 9 indexed citations
20.
Estlin, EJ, et al.. (1996). Successful treatment of non-familial haemophagocytic lymphohistiocytosis with interferon and gammaglobulin.. Archives of Disease in Childhood. 75(5). 432–435. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Grazia Zurlo Breakdown of academic impact, for papers by Hee Young Ju Breakdown of academic impact, for papers by L. Manil Breakdown of academic impact, for papers by Bertino Breakdown of academic impact, for papers by G. Landbeck Breakdown of academic impact, for papers by Carlos Alemany Breakdown of academic impact, for papers by Hideko Tasaka Breakdown of academic impact, for papers by Juliet Hananian Breakdown of academic impact, for papers by Wafaa M. Rashed Breakdown of academic impact, for papers by Patrick Cobb
Rankless by CCL
2026